TY - JOUR
T1 - An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies
T2 - One Recommendation for All?
AU - Zhou, Amy
AU - Holmes, Holly M.
AU - Hurria, Arti
AU - Wildes, Tanya M.
N1 - Funding Information:
Funding This publication was made possible by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and grant number UL1TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Funding Information:
The contents of this study are solely the responsibility of the authors and do not necessarily represent the official view of the NCI, NCATS or NIH. This publication was made possible by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and grant number UL1TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the NIH. Tanya Wildes receives research funding from Janssen and has consulted for Carevive Systems. Arti Hurria is a principal investigator for Celgene and Novartis, and a consultant for Boehringer Ingelheim Pharmaceuticals and Pieran Biosciences. Amy Zhou, Holly Holmes, Arti Hurria and Tanya Wildes declare that they have no conflicts of interest directly relevant to the content of this study.
Publisher Copyright:
© 2018, Springer International Publishing AG, part of Springer Nature.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Background: There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients. Objective: The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics. Methods: A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care. Results: Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated. Conclusions: These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy.
AB - Background: There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients. Objective: The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics. Methods: A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care. Results: Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated. Conclusions: These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85044438733&partnerID=8YFLogxK
U2 - 10.1007/s40266-018-0538-2
DO - 10.1007/s40266-018-0538-2
M3 - Article
C2 - 29589223
AN - SCOPUS:85044438733
SN - 1170-229X
VL - 35
SP - 459
EP - 465
JO - Drugs and Aging
JF - Drugs and Aging
IS - 5
ER -